🇬🇧·1d agoIndustry
Imfinzi plus Imjudo combined with lenvatinib and TACE demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in embolisation-eligible unresectable liver cancer in EMERALD-3 Phase III trial
Publisher
A
AstraZeneca RSS
UK
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on astrazeneca.com
Leave the platform to read the original full article on the publisher site.
Source: AstraZeneca RSS
Scope: Industry
Related coverage
More related coverage
Menicon·5h ago
Menicon Renames Its Sales Subsidiaries in Malaysia and Indonesia – Promoting Brand Integration and Business Expansion in Southeast Asia –
Bristol Myers Squibb (Global)·6h ago
Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026
Eli Lilly·14h ago
La FDA aprueba Foundayo™ (orforglipron) de Lilly, la Ăşnica pastilla GLP-1 para la pĂ©rdida de peso que puede tomarse a cualquier hora del dĂa sin restricciones de comida o agua
Abeona Therapeutics·18h ago
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in New York
CLEVELAND, April 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announce...